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Although some of the transcription factors that are
required for expression of crystallins during lens devel-
opment have been identified, the molecular interactions
that contribute to enhanced crystallin expression are
not yet well defined. In this study, we designed experi-
ments to test whether the co-activators CREB-binding
protein (CBP) and/or p300 interact with c-Maf, Prox-1,
or Sox-1 to enhance transcription of crystallin genes.
Promoter regions from the mouse A-, B2-, and F-
crystallin genes were linked to a luciferase reporter.
Expression of c-Maf transactivated each of these pro-
moters. Of particular interest, co-expression of CBP or
p300 with c-Maf was found to synergistically co-activate
each promoter. CBP and p300 were less effective or in-
effective at co-activation with Prox-1 or Sox-1. Co-immu-
noprecipitation and mammalian two-hybrid experi-
ments revealed that CBP and p300 bind to c-Maf and
Prox-1 but not to Sox-1. The co-activation of c-Maf by
CBP/p300 requires histone acetyltransferase activity.
Our results suggest that c-Maf recruits CBP and/or p300
to crystallin promoters leading to up-regulation of crys-
tallin gene expression through localized histone acety-
lation and consequent chromatin re-modeling. In a pro-
moter-specific fashion, co-activation can be modulated
by Prox-1 and/or Sox-1. This modulation may help to
specify the endogenous levels of crystallin gene
expression.
During embryonic development, the ocular lens is formed as
an invagination of the surface ectoderm. As differentiation
proceeds, the lens forms a hollow sphere of epithelial cells
termed the lens vesicle (1). The cells located at the posterior
surface of the lens vesicle are induced to differentiate into the
primary lens fiber cells that elongate to fill the lens vesicle. The
lens subsequently is comprised of a monolayer of proliferative
cuboidal epithelial stem cells on the anterior surface overlying
a core of elongated fiber cells (2, 3). Lens induction is accom-
panied by localized expression of several different transcription
factors including Pax-6, Six-3, Sox-2, c-Maf, Prox-1, and Sox-1
(4). Within the developing and the mature lens there is a
distinctive pattern of crystallin gene expression. The -crystal-
lins are expressed at the lens vesicle stage, and are produced by
both lens epithelial and fiber cells. The - and -crystallins are
synthesized by the fiber cells, with the expression of most
-crystallins preceding the expression of the -crystallins (5, 6).
Altogether, the crystallins constitute more than 90% of the
soluble lens proteins (7, 8).
Gene targeting studies have shown that c-Maf, Prox1, and
Sox1 are required for lens fiber cell differentiation and crystal-
lin gene expression (9–11). c-Maf is required for expression of
all three major crystallin gene families. Prox-1 and Sox-1 are
specifically required for the expression of -crystallins (10–12).
Maf consensus binding sequences (MAREs)1 have been identi-
fied in mouse A-, B2-, and F-promoter regions (9, 10, 13).
Prox-1 and Sox-1 responsive elements are also present in the
F-crystallin promoter region (9, 12). Recently, it has been
reported that Prox-1 and Six-3 act antagonistically to regulate
the F-crystallin promoter (12). It is not yet known how c-Maf,
Prox-1, and Sox-1 interact with each other to regulate crystal-
lin gene expression. It is also not known how these transcrip-
tion factors specify the remarkably high levels of crystallin
gene expression seen in lens cells.
CBP (CREB-binding protein) and p300 are well known tran-
scriptional co-activators that have histone acetyltransferase
(HAT) activity (14, 15). They interact with many transcription
factors and are required for cell differentiation and tissue de-
velopment (16). CBP/p300 can be recruited to promoters by
direct interaction with DNA-binding transcription factors or as
components of large complexes containing other cofactors such
as P/CAF, SRC-1, and the ACTR/p/CIP group of proteins (17,
18). In previous studies we showed that inhibition of CBP/p300
activity in vivo (by expression of adenoviral E1A proteins in the
lens of transgenic mice) resulted in inhibition of fiber cell
differentiation and loss of - and -crystallin gene expression
(19). In the present study, we used a cell culture system to
investigate the possibility that CBP and/or p300 may interact
directly with the transcription factors that regulate crystallin
gene expression.
We generated three crystallin promoter-luciferase reporters
(A, B2, and F), as well as a MARE-TK-luciferase reporter,
and transfected COS-1 and human lens epithelial cells (HLEC-
B3) with each reporter and with plasmids encoding c-Maf,
Prox-1, and/or Sox-1 in the presence or absence of CBP or p300.
Our results indicate that the crystallin promoters are syner-
gistically co-activated by c-MafCBP and c-Mafp300 complexes.
CBP and p300 bind directly to c-Maf and co-activation is de-
pendent upon HAT activity. We also demonstrate that Prox-1
can enhance, and Sox-1 can inhibit, this co-activation. Thus,
lens-specific transcription factors interact with CBP and/or
p300 to provide differential regulation of individual crystallin
gene expression.
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EXPERIMENTAL PROCEDURES
Plasmids for Transfection
Reporter Plasmids—A 624-bp B2-crystallin promoter (614/10)
and a 1367-bp (1357/10) F-crystallin promoter were amplified from
mouse genomic DNA using primers 5-ATAGAACCCAGGACCACCAG-
/5-GAGTGCCGTGAAGCCAGGCT for B2-crystallin and 5-GCCCCA-
CCTGCAACAAACAAC/5-GGCAGGTCAGATGGGATGGTG for F-
crystallin (20, 21). The PCR products were inserted upstream of the
luciferase reporter in the pGL3 vector (Promega). The A-crystallin
promoter was isolated from CPV2 (22) by digestion with KpnI and
BamHI. For the MARE-TK construct, the herpes simplex virus TK
promoter (109 to 18) was cut out of pTK3-Luc2 via the BglII and
HindIII sites and inserted into the BglII/HindIII sites of pGL3 to create
pGL3-TK-Luc. The Maf response element, MARE, was generated by
annealing the oligonucleotides 5-GTACCTGCTGACTCAGCAACATT-
GTTGCTGACTCAGCACG and 5-CTAGCGTGCTGAGTCAGCAA-
CAATGTTGCTGAGTCAGCAG, followed by phosphorylation with T4
polynucleotide kinase and ligation upstream of the TK promoter in
pGL3-TK-Luc. The G5E1b-Luc plasmid contains 5 copies of a Gal4-
binding site (G5) linked to an E1b minimal promoter driving the lucif-
erase reporter, as described previously (23).
Plasmids for Expressing Transcription Factors—The plasmids
pCMX-D, pCMX-VP16-N, and pCMX-Gal4-N have been described else-
where (23–25). Full-length c-Maf, Prox-1, Sox-1, CBP, p300, E1AN
(26), and E1ACR2 (26) cDNAs were cloned into the pCMX-D expres-
sion vector downstream from the cytomegalovirus promoter. The p300
mut1504 construct has a point mutation at amino acid 1504 of human
p300 (alanine codon substituted for a tyrosine codon). The p300 1430–
1504 clone has amino acids 1430 to 1504 deleted from the human p300.
The p300 mut1504 and 1430–1504 constructs were made by PCR
amplification with Pfu DNA polymerase as described (27), with both
constructs being confirmed by sequencing. For the VP16-cMaf, VP16-
Prox1, and VP16-Sox1 constructs, primers for c-maf (5-GTAGGTACC-
GCTTCAGAACTGGCAATGAAC and 5-GTAGCTAGCTGGGATCGC-
GTGTCACACTCA), Prox-1 (5-GATGGTACCCCTGACCATGACAGCA-
CAGCC and 5-CCAAGGGGGAATTCTTCTATCCATACATTC), and
Sox-1 (5-GCGGGTACCTACAGCATGATGATGGAGACC and 5-GCG-
GAATTCCTAGATGTGCGTCAGGGGCAC) were used to amplify the
entire coding regions (except for the ATG) from cDNA clones. The PCR
products were digested with Asp718/NheI and cloned in-frame into the
pCMX-VP16-N vector. For the mammalian two-hybrid assays, full-
length human p300 or domains of p300 were cloned into pCMX-Gal4-N
using restriction digests or PCR amplification with Pfu DNA
polymerase to generate the required DNA fragments. All constructs
were confirmed by sequencing. For the c-Maf-HAT construct, primers
5-TTAGGTACCGCTTCAGAACTGGCAATGAAC and 5-GCGGAATT-
CCATGAAAAATTCGGGAGAGG were used to amplify the c-maf coding
sequence without the stop codon. The PCR product was digested with
Asp718/EcoRI and cloned into the pCMX-D vector. The p300 HAT
domain (amino acids 1190–1970) was amplified using primers 5-GC-
GGAATTCACTTATTACAGTTACCAGAACAGG AND 5-CTCGAGTCG-
ACCAGGTGGGTTCATACCCATGGG. The PCR product was digested
with EcoRI/SalI and ligated in-frame to the 3 end of c-maf.
Plasmids for Immunoprecipitation—A start codon followed by two
“Myc” tag sequences (EQKLISEEDL) was placed in-frame and up-
stream from c-Maf, Prox-1, or Sox-1 coding sequences in the pSG5
(Stratagene) vector. For the vector pSG5-p300-F2, two “FLAG” tag
sequences (DYKDDDDK) followed by a stop codon were placed in-frame
and downstream from the human p300 cDNA sequence corresponding
to amino acids 1–2378.
Control Plasmids—The control plasmids pCMX--gal and TK-
growth hormone have been described elsewhere (23–25).
Cell Culture, Transient Transfections, and Mammalian
Two-hybrid Assays
COS-1 and HLEC-B3 cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum overnight at
37 °C before transfection. For transient transfections, 200 ng of a lucif-
erase reporter were co-transfected with 50 ng of pCMX-gal control
plasmid plus 20–320 ng of one or more of the transcripition factor
plasmids per well of a 24-well tissue culture dish unless otherwise
indicated. For the mammalian two-hybrid assays, 200 ng of pG5E1b-
Luc reporter plasmid, 50 ng of TK-growth hormone control plasmid, and
100 ng each of the pCMX-Gal4-N and pCMX-VP16-N chimeric expres-
sion plasmids were used per well of a 24-well tissue culture dish.
Plasmid DNAs were mixed with 2.5 M CaCl2 and then added to BES-
buffered saline. The DNA mixtures were added to the cells in 1 ml of
fresh Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum. After incubation for 8–12 h, the cells were washed with
phosphate-buffered saline, then incubated with Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum for 24–36 h
prior to harvesting and assaying for luciferase activity on a Dynex MLX
luminometer as described (27). The -gal activity was assayed using the
Tropix -galactosidase kit according to the manufacturer’s instructions
(Tropix). Growth hormone secretion was assayed using the human
growth hormone transient gene expression kit according to the manu-
facturer’s instructions (Nichols Institute). Luciferase expression was
normalized to the -gal or growth hormone control. Transfections were
done in triplicate and were replicated with similar results in at least
three independent experiments. Results are the mean  S.D. from
three individual experiments. All statistical analyses were performed
with two-tailed Student’s t tests using Microsoft Excel software. Data
were considered to be significantly different for p  0.05.
Co-immunoprecipitation
COS-1 cells in 10-cm plates were transfected with Myc-tagged c-Maf,
Prox-1, or Sox-1 plus FLAG-tagged p300 and/or full-length CBP in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum. Cells were collected 36 h after transfection. Nuclear extracts
were prepared following the protocol of Schrieber et al. (28). In addition,
lenses from newborn FVB mice were collected and sonicated in protein
lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% Triton X-100,
1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, protease inhib-
itors (Mixture Tablets, from Roche Molecular Biochemicals, one tablet
in 15–20 ml solution), 5 mM EDTA, pH 8.0, 10 mM EGTA, pH 8.0), then
centrifuged to harvest the supernatant. The lens lysates (2 mg) and the
transfected COS-1 cell nuclear extracts (1 mg) were precleared by
addition of 50 l of protein G-agarose beads (1:1 dilution in RIPA wash
buffer containing 50 mM Tris-HCl, 0.1% Nonidet P-40, 1 mM EDTA, 672 D. D. Moore, unpublished data.
FIG. 1. Crystallin promoter report-
ers. The constructs with the A-, B2-,
and F-crystallin promoters linked to a
luciferase reporter are depicted. Potential
c-Maf recognition sites are located at
110 to 98 in the A and B2 promot-
ers, and at47 to35 in the F promoter
(30–32). The F promoter also contains a
potential Prox-1 (174 to 151) and a
Sox-1 (63 to 47)-binding site (9, 12).
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mM NaCl). After centrifugation, supernatants were collected and incu-
bated with mouse monoclonal anti-p300 antibody (Sigma), anti-CBP
antibody (Santa Cruz, A-22), anti-FLAG M2 monoclonal antibody (Sig-
ma), or anti-Myc monoclonal antibody (Roche Molecular Biochemicals).
After a 3-h incubation at room temperature, 50 l of protein A- or
G-agarose beads (1:1 dilution in RIPA buffer) were added and incubated
overnight at 4 °C. After washing three times in RIPA buffer, bound
proteins were eluted with 2  SDS sample buffer. Proteins were
separated by SDS-PAGE (4–15% Tris-HCl), and transferred onto
polyvinylidene difluoride membranes (Invitrogen), followed by immu-
noblotting with anti-c-Maf (Santa Cruz), anti-CBP, anti-FLAG, or
anti-Myc antibodies (1:1000 dilution) and detection by enhanced
chemiluminesence (ECL) (Amersham Pharmacia Biotech). After
SDS-PAGE separation, the proteins were also visualized by Coomas-
sie Brilliant Blue staining.
RESULTS
Transactivation of Crystallin Promoters by c-Maf, Prox-1,
and Sox-1—Our previous transgenic studies showed that lens-
specific expression of adenoviral E1A proteins that bind to
CBP/p300 causes inhibition of lens fiber cell differentiation and
nearly complete loss of crystallin expression (19). Although the
lens phenotypes resembled the c-maf knockout mice (9), the
expression of c-maf in lens fiber cells expressing the E1A trans-
gene was not affected (19), suggesting that c-Maf-mediated
transactivation of crystallin genes may require CBP/p300 co-
activation. Previous studies have shown that Prox-1 and Sox-1,
like c-maf, are expressed at early stages of lens development,
and are required for specific crystallin (-crystallin) expression
(10, 11). We therefore postulated that expression of lens-spe-
cific crystallin genes might require interactions of ocular tran-
scription factors with the co-activators CBP and p300.
To test this prediction, we designed experiments to compare
the abilities of c-Maf, Prox-1, and Sox-1 to transactivate crys-
tallin promoters. c-Maf has previously been shown to transac-
tivate the F-crystallin promoter in a cell culture system (29).
An electrophoretic mobility shift assay showed that c-Maf could
also bind to DNA fragments from the mouse B2- and A-
crystallin promoters (9). Putative MAREs have been identified
in the mouse A- (position 110/98), B2- (position 110/
98), and F- (position 47/35) crystallin promoters (9, 30–
32). Based on these studies, we subcloned mouse A, B2, and
F promoter DNA fragments into the pGL3 basic luciferase
vector (Fig. 1) for transient transfection studies. Monkey kid-
ney cells (COS-1) were co-transfected with each crystallin re-
porter (Fig. 1) and with plasmids encoding the different tran-
scription factors. As predicted, c-Maf transactivated the three
promoters in a dose-dependent fashion (Fig. 2, A–C). Sox-1
transactivated the F-crystallin promoter in a dose-dependent
fashion, similar to c-Maf (Fig. 2C). Sox-1 also stimulated the
B2 promoter, but less strongly than c-Maf (Fig. 2B). Prox-1
(80 ng) stimulated the B2- and F-crystallin promoters only
about 2-fold (Fig. 2, B and C). To determine whether these
FIG. 2. Transactivation of crystallin promoters by c-Maf, Prox-1, and Sox-1. A–C, COS-1 cells were transfected with A-, B2-, or
F-crystallin reporters and plasmids encoding c-Maf, Prox-1, or Sox-1. Expression of c-Maf activated all three promoters. There was no significant
A promoter transactivation by Prox-1 or Sox-1 (p  0.05) (A). Prox-1 activated B2- and F-crystallin promoters about 2-fold (p  0.01) (B and
C). Sox-1 significantly transactivated the F reporter in a dose-dependent manner (C), and also activated the B2 promoter (p 0.05) (B). D, COS-1
cells were co-transfected with each crystallin reporter and 60 ng of the plasmids encoding c-Maf, Prox-1, and Sox-1 as indicated. Co-expression of
Prox-1 and c-Maf enhanced transactivation of the three promoters (lanes 5, 11, and 17) (p  0.05, p  0.001, and p  0.05), especially B2 (lane
11). Similarly, co-expression of Sox-1 with c-Maf significantly increased F promoter activation (lane 18) (p  0.001), but repressed A promoter
activity (lane 6) (p  0.01). Fold activation is expressed relative to the Luc/-gal ratio seen after co-transfection of each specific reporter (A, B2,
or F) with the empty pCMX-D expression vector, which was arbitrarily set at 1.
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transcription factors can collaborate to transactivate crystallin
promoters, co-transfections were done using 60 ng of each
transcription factor. We observed cooperative transactivation
using Prox-1 plus c-Maf, especially for the B2 reporter (Fig.
2D, lanes 5, 11, and 17) (p  0.05). Co-expression of Sox-1 with
c-Maf significantly increased F promoter activation (Fig. 2D,
FIG. 3. CBP/p300 co-activation. A–C, COS-1 cells were co-transfected with each crystallin reporter and 60 ng each of the plasmids encoding
c-Maf, Prox-1, or Sox-1 in the presence or absence of CBP or p300. Expression of CBP or p300 significantly increased (i.e. co-activated)
c-Maf-dependent activation of each crystallin promoter (about 3-fold) (lanes 7 and 8 in A–C). None of the other transcription factors gave more than
a 2-fold increase in promoter activity, even in the presence of CBP or p300. D, human lens epithelial cells (B3) were co-transfected with the
A-crystallin reporter and 60 ng each of the plasmids encoding c-Maf, Prox-1, or Sox-1 in the presence or absence of CBP. We observed stimulation
of the A promoter by c-Maf (3-fold) (lane 2). Co-activation was seen with Prox-1 plus c-Maf and with CBP plus c-Maf co-transfections (lanes 5 and
8) (p  0.05). CBP did not significantly co-activate Prox-1 or Sox-1 activity (p  0.05) (lanes 9 and 10). Co-expression of Sox-1 with c-Maf repressed
the c-Maf-mediated A promoter activation (p  0.001) (lane 6). E, COS-1 cells were co-transfected with A reporter and c-Maf, CBP, or p300, plus
or minus two E1A constructs (E1AN or E1ACR2). Co-expression of E1ACR2, which binds to CBP/p300, blocks CBP or p300 co-activation of the
A promoter (p  0.001) (lanes 9 and 12). Fold activation is expressed relative to the Luc/-gal ratio obtained after co-transfection of the specific
reporter (A, B2, or F) with the empty pCMX-D expression vector, which is arbitrarily set at 1.
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lane 18) (p 0.001), but Sox-1 repressed c-Maf stimulation of the
A promoter (lane 6, p  0.01). Except for activation of B2 by
c-Maf and Prox-1, the co-activation did not significantly exceed
the sum of the activations by each individual transcription factor,
suggesting a general absence of synergistic interaction.
CBP and p300 Enhance c-Maf-mediated Transactivation of
Crystallin Genes—To assay for CBP/p300 co-activation of crys-
tallin promoter activity, COS-1 cells were co-transfected with
each of the three crystallin reporters and plasmids encoding
c-Maf, Prox-1, or Sox-1 in the presence or absence of CBP or
p300. Although CBP or p300 alone did not stimulate any of the
crystallin promoters (Fig. 3, A–C, lanes 5 and 6, p  0.05), both
proteins enhanced (or co-activated) c-Maf-dependent crystallin
promoter activity for all three promoters (lanes 7 and 8, p 
0.01). In contrast, expression of CBP or p300 did not signifi-
cantly alter the promoter activation induced by Prox-1 or Sox-1
(p  0.05) (Fig. 3, A–C). Human lens epithelial cell line B3
(HLEC-B3) was also used for transient transfection assays
(Fig. 3D). Synergistic co-activation of the A-crystallin pro-
moter was seen upon transfection with CBP plus c-maf (p 
0.01, lane 8). Stimulation of the promoter also occurred with
c-Maf plus Prox-1 (p 0.05, lane 5). Co-activation was minimal
for the other combinations of factors. In addition, COS-1 cells
were co-transfected with the A-crystallin promoter and c-maf,
CBP, or p300, plus two versions of the E1A gene of adenovirus:
E1AN (which does not bind to CBP/p300) and E1ACR2
(which binds to and inhibits both CBP and p300) (19). Expres-
sion of E1ACR2 completely blocked co-activation of the A-
crystallin promoter (p  0.001, Fig. 3E, lanes 9 and 12).
Prox-1 Enhances CBP/p300 Co-activation of the B2 Pro-
moter, whereas Sox-1 Represses Co-activation—Since Prox-1
and c-Maf can collaborate to stimulate the B2 promoter (Figs.
2D and 3D), we tested the effects of Prox-1 and Sox-1 on
c-Maf/CBP/p300 co-activation of this promoter (Fig. 4). Prox-1
stimulated co-activation (p  0.01, compare lanes 5 and 6 to
lanes 3 and 4 in Fig. 4A), whereas Sox-1 significantly inhibited
CBP/p300 co-activation of c-Maf (p  0.001) (lanes 7 and 8). To
test whether these interactions required Prox-1- or Sox-1-bind-
ing sites, an artificial luciferase reporter (MARE-TK-Luc) was
generated by inserting a c-Maf-binding site (TGCTGACT-
CAGCA) upstream of the TK promoter (Fig. 4B). When COS-1
cells were co-transfected with the MARE-TK-Luc reporter and
plasmids encoding c-Maf, Prox-1, Sox-1, and CBP or p300, we
again observed stimulation of co-activation by Prox-1 (p 0.05,
Fig. 4C, compare lanes 11 and 12 to lanes 9 and 10), but
inhibition by Sox-1 (p  0.001, lanes 13 and 14). Prox-1 alone
did not activate this reporter (Fig. 4C, lane 3), indicating that
Prox-1 does not co-activate by binding directly to the MARE.
Instead, our data suggest that Prox-1 can be indirectly re-
cruited to MARE by the c-MafCBP/p300 complex, as shown in
Fig. 4D. These results indicate, but do not prove, that c-Maf
and Prox-1 may bind to CBP/p300 simultaneously.
Binding of CBP/p300 to c-Maf and Prox-1—Since CBP and
p300 have been shown to bind to numerous sequence-specific
transcription factors (16), we tested whether c-Maf, Prox-1, or
Sox-1 can bind directly to CBP/p300 by co-immunoprecipita-
tion. When COS-1 cells were co-transfected with Myc-tagged
c-Maf and FLAG-tagged p300, antibodies to either Myc or
FLAG were able to co-precipitate the two proteins (Fig. 5A, lane
4). Similar results were obtained when COS-1 cells were co-
transfected with Myc-tagged c-Maf and full-length CBP (Fig.
5B). When COS-1 cells were co-transfected with Myc-tagged
Prox-1 or Myc-tagged Sox-1 plus FLAG-tagged p300, the anti-
FLAG antibody was able to co-precipitate Prox-1 but not Sox-1
(Fig. 5C, bottom panel, lanes 6 and 5, respectively). To investi-
gate whether c-Maf normally is bound to CBP/p300 in the lens,
co-immunoprecipitations were performed using newborn
mouse lens lysates. As shown in Fig. 5D, anti-p300 antibody
precipitated a c-Maf protein.
To further analyze the binding of c-Maf and Prox-1 to p300,
a mammalian two-hybrid assay was established (Fig. 6). The
DNA-binding domain of Gal4 was fused to full-length p300 and
to several subregions of p300. At the same time, full-length
c-Maf, Prox-1, and Sox-1 were linked to the transactivation
domain of the herpes simplex virus protein VP16. The reporter
construct (G5E1b-Luc) contains an E1b promoter cloned down-
FIG. 4. Interactions between Prox-1 or Sox-1 and c-MafCBP/
p300. A, COS-1 cells were co-transfected with the B2 reporter and 60
ng each of the plasmids encoding c-Maf, Prox-1, Sox-1, CBP, and/or
p300. Expression of Prox-1 enhanced CBP/p300-mediated co-activation
(p  0.01) (lanes 5 and 6), whereas co-expression of Sox-1 repressed the
co-activation (p  0.01) (lanes 7 and 8). B, diagram of the MARE-TK-
Luc construct. C, COS-1 cells were co-transfected with this reporter and
60 ng each of the plasmids encoding c-Maf, Prox-1, or Sox-1 in the
presence or absence of CBP or p300. Prox-1 was found to increase
co-activation by c-MafCBP (p  0.05) (lane 11) or c-Mafp300 (p  0.05)
(lane 12). In contrast, Sox-1 inhibited co-activation (p  0.01) (lanes 13
and 14). Fold activation is expressed relative to the Luc/-gal ratio
obtained after co-transfection of the specific reporter (B2 or MARE-
TK) with the empty pCMX-D expression vector, which is arbitrarily set
at 1. D, diagrammatic representation of MARE-TK-Luc regulation.
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stream of five copies of the Gal4-binding site and upstream
from a luciferase reporter (Fig. 6A). Since p300 alone does not
transactivate this promoter, expression of the reporter requires
interaction between p300 and c-Maf, Prox-1, or Sox-1 to recruit
the VP16 transactivator to the vicinity of the promoter. As
shown in Fig. 6B, Gal4-p300 plus VP16 (without c-Maf) slightly
induced transcription (lane 3). When Gal4-p300 was co-ex-
pressed with VP16-c-Maf (lane 7), a dramatic increase in lucif-
erase expression was obtained. Co-expression of VP16-c-Maf
with Gal4-p300 (1–1235), which has the amino-terminal half of
p300 fused to Gal4, was also able to increase transcriptional
activity (lane 8). Co-expression of Gal4-p300 (1256–2415) with
VP16-c-Maf showed minimal activation (lane 9). Subregions of
p300 containing amino acids 1–150, 180–662, and 595–1068
were therefore linked to Gal4 and tested (Fig. 6C). When Gal4-
p300 (180–662) was co-expressed with VP16-c-Maf (lane 8), we
observed a dramatic increase in transcriptional activity. Thus,
c-Maf binds to the region of p300 that contains the first zinc
finger and the CREB-binding domain (Fig. 6D).
By comparison, when COS-1 cells were co-transfected with
VP16-Prox-1 or VP16-Sox-1 plus Gal4-p300 (full-length), ex-
pression of Prox-1 (Fig. 7, lane 8) but not Sox-1 (Fig. 7, lane 9)
dramatically increased promoter activation, confirming that
Prox-1 but not Sox-1 can directly bind to full-length p300.
When the cells were co-transfected with VP16-Prox-1 and var-
ious subregions of p300 (1–1235, 1256–2415, and 1190–1966)
fused to Gal4, we did not observe significant changes in pro-
moter activation (Fig. 7, lanes 13–15), suggesting that the
binding of Prox-1 to p300 may be dependent upon the configu-
ration of full-length p300.
FIG. 5. c-Maf and Prox-1 bind to CBP/p300. A, co-immunoprecipitation of c-Maf with p300. Lane 1, untransfected COS-1 cell nuclear extract
as a negative control; lane 2, cells were transfected with Myc-tagged c-Maf; lane 3, cells were transfected with FLAG-tagged p300; lane 4, cells were
co-transfected with Myc-tagged c-Maf and FLAG-tagged p300. Nuclear extracts were immunoprecipitated (IP) with anti-Myc or anti-FLAG
antibody, the complexes were analyzed by SDS-PAGE and Western blotting (WB) using anti-Myc or anti-FLAG antibodies as denoted in the figure.
B, co-immunoprecipitation of c-Maf with CBP. Lane 1, untransfected COS-1 cell nuclear extract; lane 2, cells were transfected with Myc-tagged
c-Maf; lane 3, cells were transfected with full-length CBP; lane 4, cells were co-transfected with Myc-tagged c-Maf and full-length CBP. Nuclear
extracts were immunoprecipitated (IP) with anti-Myc or anti-CBP antibodies and immunocomplexes were separated by SDS-PAGE. Western blots
(WB) were detected with anti-Myc or anti-CBP antibodies as denoted in the figure. C, co-immunoprecipitation of Prox-1 but not Sox-1 with p300.
Lane 1, untransfected COS-1 cell nuclear extract; lane 2, cells were transfected with Myc-tagged Sox-1; lane 3, cells were transfected with
Myc-tagged Prox-1; lane 4, cells were transfected with FLAG-tagged p300; lane 5, cells were co-transfected with Myc-tagged Sox-1 and
FLAG-tagged p300; lane 6, cells were co-transfected with Myc-tagged Prox-1 and FLAG-tagged p300. Nuclear extracts were immunoprecipitated
(IP) with anti-Myc or anti-FLAG antibodies. Western blots were detected with anti-Myc antibody. D, co-immunoprecipitation of c-Maf with
CBP/p300 in mouse lens tissue. Lane 1, lens lysate (2 mg) from newborn FVB mice was immunoprecipitated with anti-p300 antibody (Sigma, also
recognizes CBP protein); lane 2, lens lysate (2 mg) from newborn FVB mice was immunoprecipitated with mouse IgG as a control. Immunocom-
plexes were separated by SDS-PAGE and immunoblotted with anti-c-Maf antibody.
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CBP/p300 Co-activation Requires HAT Activity—To ascer-
tain whether the HAT activity of CBP/p300 is essential for
co-activation of the crystallin genes, we constructed plasmids
encoding two different mutations of p300. The p300 mut1504
clone has a point mutation in the HAT domain (alanine codon
substituted for a tyrosine codon at amino acid 1504), whereas
1430–1504 has a deletion in the HAT domain (from amino
acids 1430 to 1504). Mut1504 corresponds to a point mutation
in CBP (mutation 1541) found to eliminate HAT activity (33).
The 1430–1504 deletion removes several important domains
of p300 that correspond to motifs required for CBP HAT activ-
ity (33). Co-expression of c-Maf with either p300 mut1504 or
1430–1504 produced no co-activation of the F-crystallin pro-
moter or the MARE-TK promoter (Fig. 8, A and B, last two
lanes). To test whether the HAT activity of CBP/p300 is suffi-
cient to co-activate c-Maf, we constructed a plasmid encoding a
c-Maf-HAT fusion protein (c-maf coding region fused with the
HAT domain of p300). We found that expression of the c-Maf-
HAT fusion protein activated the F-crystallin and MARE-TK
promoters to the same extent as c-Maf plus p300 (Fig. 8, C and
D, two lanes on the right), indicating that histone acetylation
is sufficient to enhance c-Maf activation of crystallin gene
expression.
DISCUSSION
We have used a cell culture system to begin to study the
mechanism(s) by which CBP and p300 become involved in
crystallin promoter activation. We demonstrate that represent-
ative crystallin promoters are transactivated by the lens-spe-
cific c-Maf transcription factor, and that the promoter activity
can be significantly enhanced by the co-activators CBP and/or
FIG. 6. Binding of c-Maf to a specific region of p300. A, diagrammatic representation of our mammalian two-hybrid assay. COS-1 cells were
co-transfected with a pG5E1b-luciferase reporter plus plasmids encoding the Gal4 DNA-binding domain (DBD) either alone or fused to various
regions of p300, and with a plasmid expressing the VP16 acidic activation domain (AD) either alone or fused to c-Maf. Expression of the luciferase
reporter is dependent upon interaction between Gal4-p300 and VP16-c-Maf chimeras to recruit VP16 to the E1b-TATA promoter to initiate
transcription. B, co-expression of full-length Gal4-p300 (lane 7) or the amino terminus of p300 (amino acids 1–1235) (lane 8) together with
VP16-c-Maf significantly increased luciferase activity. C, VP16-c-Maf interacts specifically with Gal4-p300-(180–662) (lane 8), which includes the
first zinc finger domain and the CREB-binding domain of p300 (shown in D). Fold activation is expressed relative to luciferase/growth hormone
activity obtained after co-transfection of the specific reporter (G5E1b reporter) and an empty expression vector. D, schematic drawing of p300.
FIG. 7. Binding of Prox-1 to p300. Similar to c-Maf (lane 7), co-
expression of VP16-Prox-1 but not VP16-Sox-1 together with full-length
Gal4-p300 dramatically increased the luciferase activity in the mam-
malian two-hybrid assay (lanes 8 and 9). However, co-expression of
VP16-Prox-1 with various subregions of p300 (1–1235, 1256–2415, and
1189–1966) fused to Gal4 did not activate the reporter (lanes 13–15).
Fold activation is expressed relative to luciferase/growth hormone ac-
tivity obtained after co-transfection of the specific reporter (G5E1b
reporter) and empty expression vector.
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p300. Co-activation is mediated by binding of c-Maf to a specific
domain of p300 (and presumably also of CBP). In addition,
co-activation involves histone acetyltransferase activity and
can be influenced by Prox-1 and Sox-1. Our results indicate
that high levels of crystallin gene expression in the lens are
dependent upon binding of c-Maf plus CBP and/or p300 to
specific crystallin promoters, followed by localized histone
acetylation and, we predict, consequent chromatin remodeling.
Regulation of A-Crystallin—In the mouse, -crystallins are
first expressed at the lens vesicle stage. Both A- and B-
crystallins are synthesized by lens epithelial and early fiber
cells. At later stages A-crystallin continues to be expressed in
both cell types (although more strongly in early fiber cells), but
B-crystallin persists only in epithelial cells (34). Previous
studies indicated that transcriptional regulation of the mouse
A-crystallin gene is dependent upon a cAMP-responsive ele-
ment (DE1/CRE) and a Pax-6-binding site (30), indicating that
Pax-6 plays a critical role in transactivation of the A-crystal-
lin gene. More recently, c-maf null mice were found to have
defects of A-crystallin expression (9), and a Maf responsive
element (13) was found to be present in the A-crystallin pro-
moter region. Consistent with these later findings, our results
indicate that expression of c-Maf significantly transactivates
the A-crystallin promoter. We also found that c-Maf can re-
cruit the co-activators CBP/p300 to the A-crystallin promoter.
Although Pax-6 is required for A-crystallin expression (30),
the requirement may be indirect since recent evidence shows
that c-maf expression can be up-regulated by Pax-6 (35). In our
tissue culture system, we co-expressed Pax-6 plus c-Maf and
CBP or p300 but did not see a significant further increase in
promoter activity (data not shown). Therefore, we predict that
Pax-6 does not directly interact with the c-MafCBP/p300 com-
plex. Currently, there is no evidence that the 400-bp A-crys-
tallin promoter that we tested here contains Prox-1- or Sox-1-
binding sites. We did not observe significant transactivation of
the A-crystallin promoter by Prox-1 or Sox-1. Interestingly,
expression of Sox-1 significantly repressed c-Maf transactiva-
tion and c-MafCBP/p300 co-activation of the A promoter (p 
0.001, Figs. 2D and 3D). It is unknown whether Sox-1 competes
with c-Maf for binding to the A-crystallin promoter.
Regulation of B2-crystallin—The -crystallins can be di-
vided into A- (A1, A2, A3, and A4) and B- (B1, B2, and B3)
crystallins, and are considered as early markers of lens fiber
cell differentiation (7). Similar to the A-crystallin promoter, a
putative MARE has been identified in the B2-crystallin pro-
moter in both mouse and rat (9, 36). A recent study (37) indi-
cates that c-Maf is not essential for the activity of the B2-
crystallin promoter in the rat lens. Instead, a putative Sox-
binding site at 164/159 and a positive element at 14/7
seem to be the primary regulatory elements (37). In our trans-
fection study, we observed weaker stimulation of the B2 pro-
moter by Sox-1 than by c-Maf. In fact, Sox-1 was found to block
c-MafCBP/p300 mediated co-activation, suggesting that Sox-1
may not be a significant positive regulator of the mouse B2-
crystallin gene. We did find that c-Maf-mediated transactiva-
tion of the mouse B2-crystallin promoter activity can be en-
FIG. 8. CBP/p300 co-activation requires HAT activity. A and B, COS-1 cells were co-transfected with the F-crystallin reporter or the
MARE-TK-luc reporter plus plasmids encoding c-Maf, full-length p300, p300 with a point mutation (mut1504), or p300 with a deletion (1430–
1504) in the HAT domain. The p300 mutants did not co-activate either reporter. C and D, COS-1 cells were co-transfected with the F-crystallin
reporter or the MARE-TK-luc reporter and plasmids encoding c-Maf, full-length p300, or c-Maf-HAT (encoding c-Maf fused with the HAT domain
of p300). Expression of the c-Maf-HAT fusion protein was sufficient to co-activate both reporters (p  0.001). Fold activation is expressed relative
to luc/gal activity obtained after co-transfection of the specific reporter (F or MARE-TK) and an empty expression vector.
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hanced by Prox-1 (Fig. 2D, lane 11). Since this cooperative
stimulation was significant with the MARE-TK-luc reporter
(p  0.05, Fig. 4C, lane 7), which does not have a Prox-1-
binding site, and since Prox-1 can bind to CBP/p300, it suggests
that Prox-1 may be recruited indirectly to the mouse B2-
crystallin promoter. Developmental regulation of the B2-crys-
tallin promoter may involve an additional level of complexity
that is not reflected by our tissue culture assays. Previous
studies have shown that expression of mouse B2-crystallin
mRNA is undectable at embryonic day 11.5 (E11.5) (9), and
that mouse (and rat) B2-crystallin protein levels are low prior
to birth, but are up-regulated postnatally (38). It is not yet
known whether protein levels reflect transcriptional or post-
transcriptional changes during development. Although our cur-
rent and previous studies (9, 19) indicate that c-Maf and CBP/
p300 are necessary for high level mouse B2 promoter activity,
it is important to remember that the endogenous gene is likely
to have additional important regulatory domain(s) that are not
present in the promoter region that we tested here.
Regulation of F-crystallin—The -crystallins are encoded
by a cluster of six genes (A-F) (7). In the mouse, expression of
-crystallins begins around embryonic day 13 (E13), and is
restricted to maturing fiber cells in the lens (39). Previous
loss-of-function studies showed that mice lacking Sox-1 have an
almost complete absence of -crystallin expression (10). c-maf
and Prox-1 null mice also showed reduced expression of -crys-
tallins (9, 11). A MARE and a Sox-1-binding site are present in
the F-crystallin promoter region (10, 29). Our experimental
results show that either c-Maf or Sox-1 can significantly trans-
activate the F-crystallin promoter, which is consistent with
previous findings. In addition, we found that c-Maf and Sox-1
can have a cooperative interaction at this promoter (Fig. 2D). A
recent study indicates that the F promoter also contains a
Prox-1 responsive element, and that expression of Prox-1 in
CD5A (human lens epithelial) cells significantly enhances pro-
moter activation (12). In our transfection studies using COS-1
and HLEC-B3 cell lines, we observed a slight, but significant
(p  0.05), transactivation of the F-crystallin promoter by
Prox-1. We did not observe CBP/p300 co-activation with either
Prox-1 or Sox-1 (Fig. 3C), suggesting that Prox-1- or Sox-1-
mediated transactivation of the F-crystallin gene might use
an alternative co-activator system. Given the fact that Sox-1
cooperates with c-Maf to enhance F-crystallin but repress
A-crystallin promoter activity, our studies suggest that the
patterns of crystallin gene expression in the lens are modulated
by interactions between the lens-specific transcription factors
and their co-activators.
CBP/p300 Co-activation—CBP and p300 are transcriptional
co-activators that are often required for cell differentiation and
tissue development. Since CBP and p300 have HAT activity
(14, 15, 17), histone acetylation and consequent chromatin
remodeling are considered to be important for gene activation
(40, 41). Our previous transgenic studies have shown that
c-Maf expression in the lens is not sufficient to activate - and
-crystallin expression in the absence of CBP/p300 function
(19). Our current observations provide an explicit molecular
model for the role of CBP/p300 in crystallin gene regulation,
which is consistent with previous models for CBP/p300 func-
tion. Specifically, crystallin gene expression appears to be ac-
tivated by sequence-specific binding by the c-Maf transcription
factor, recruitment of the co-activators CBP/p300, and subse-
quent localized histone acetylation. Prox-1 and Sox-1 probably
act to differentially modulate this activity for specific crystallin
genes. Our studies do not establish the mechanism(s) by which
Sox-1 can repress CBP/p300 co-activation. One possible expla-
nation is that Sox-1 can recruit repressors to block c-MafCBP/
p300 binding to the crystallin promoters. Another possible ex-
planation is that Sox-1 may indirectly inhibit the HAT activity
of CBP/p300. Although additional features of crystallin gene
regulation surely exist, our studies pinpoint the interaction
between c-Maf and CBP/p300 as being essential for the high
levels of crystallin gene expression that are seen in the fiber
cells of the ocular lens.
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